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The gamma-aminobutyric acid (GABA) metabolite gamma-hydroxybutyric
acid (GHB) shows a variety of behavioural effects when administered to ani-
mals and humans, including reward/addiction properties and absence
seizures. At the cellular level, these actions of GHB are mediated by activation
of neuronal GABAB receptors (GABABRs) where it acts as a weak agonist.
Because astrocytes respond to endogenous and exogenously applied GABA
by activation of both GABAA and GABABRs, here we investigated the action
of GHB on astrocytes on the ventral tegmental area (VTA) and the ventrobasal
(VB) thalamic nucleus, two brain areas involved in the reward and proepileptic
action of GHB, respectively, and compared it with that of the potent GABABR
agonist baclofen. We found that GHB and baclofen elicited dose-dependent
(ED50: 1.6 mM and 1.3 mM, respectively) transient increases in intracellular
Ca2þ in VTA and VB astrocytes of youngmice and rats, which were accounted
for by activation of their GABABRs and mediated by Ca
2þ release from intra-
cellular store release. In contrast, prolonged GHB and baclofen exposure
caused a reduction in spontaneous astrocyte activity and glutamate release
from VTA astrocytes. These findings have key (patho)physiological impli-
cations for our understanding of the addictive and proepileptic actions of GHB.1. Introduction
Gamma-hydroxybutyric acid (GHB) is an endogenous central nervous system
(CNS) substance that results from the metabolism of the neurotransmitter
gamma-aminobutyric acid (GABA) [1–3], but can also act as a source of neuronal
GABA [4]. In humans, exogenously administered GHB elicits a variety of behav-
ioural responses that at progressively increasing doses include sedation, memory
loss, euphoria, behavioural disinhibition, sleep and coma [2,5–8]. GHB has also
found some limited clinical use in the treatment of alcohol and opiate withdrawal
[9–12] as well as of narcolepsy and cataplexy [13–15]. In the early 1970s, GHB
emerged as a recreational drug and still remains one of the most commonly used
‘club drugs’ [16–19], with GHB overdoses accounting for a substantial proportion
of the hospital emergencies that are linked to recreational nightlife settings [20].
A neuropharmacological profile similar to that observed in humans character-
izes the behaviour of animals injected with GHB. The most extensively studied
behavioural actions ofGHB are its ability to induce self-administration and absence
seizures [3]; indeed, the systemic administration of low doses of GHB has become
themostwidely used pharmacologicalmodel of these non-convulsive seizures [21].
Thus, oral GHB induces self-administration and conditioned place preference in
mice and rats [22–25]. In addition, GHB administration leads to a moderate stimu-
lation of the dopaminergic reward system [26], and in vitro low concentration of
GHB preferentially inhibits the GABAergic neurons of the ventral tegmental area
(VTA), one of the key brain-reward areas [25,27]. Indeed, GHB induces conditioned
place preference when injected directly in the VTA [28], but not in the nucleus
accumbens, another important brain-reward area. As far as absence seizures are
concerned, the ability of GHB to elicit absence seizures is not restricted to its
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it is injected directly into the ventrobasal (VB) nucleus of the
thalamus [29], one of the key areas for the generation of these
non-convulsive seizures [30].
In bothmice and rats, all behavioural and cellular actions of
GHB, including its reward- and seizure-eliciting properties,
can be explained by it acting as aweak agonist at GABAB recep-
tors (GABABRs) [31,32], though the existence of a putative
GHB receptor site has been suggested [33] (but see [3]). Thus,
the pro-absence action of GHB is mimicked by the selective
GABABR agonist baclofen and is fully antagonized by different
selective GABABR antagonists [3], and in some studies by
NCS382, an antagonist of the putative GHB receptor site [34].
Interestingly, micromolar GHB concentrations have recently
been suggested to activate recombinant a4bd GABAARs [35],
though the physiological significance of this finding remains
obscure as these results could not be reproduced in different
brain areas, including thalamus, cerebellum and hippocampus
[36] that contain this combination of GABAAR subunits.
It is now well-established that astrocytes respond to differ-
ent neurotransmitters, includingGABA [37,38] and signal back
to neurons via the release of gliotransmitters [39,40], thus
modulating neuronal excitability and different forms of synap-
tic plasticity [41]. Thus, because astrocytes respond toGABABR
activation [42], and the VTA andVB thalamus contribute to the
behavioural actions of GHB [3], we investigated the effect of
GHB on this glial cell type in brain slices and compared it
with the selective GABABR agonist baclofen. We report that
GHB and baclofen elicit a dose-dependent increase of intra-
cellular Ca2þ ([Ca2þ]i) in VTA and VB astrocytes which
is fully accounted for by activation of their GABABRs and is
mediated by Ca2þ release from intracellular stores. In contrast
tomanyother studieswhich found that transient aswell as sus-
tained agonist-induced astrocytic [Ca2þ]i elevations result in
increased gliotransmitter release, prolongedGHB and baclofen
exposure causes a reduction in spontaneous glutamate release
from VTA astrocytes.2. Materials and methods
All experiments were performed in accordance with the Animals
(Scientific Procedures) Act 1986, UK, and with approval of local
animal welfare and ethical review bodies.(a) Slice preparation and maintaining solutions
Male and femaleWistar rats (8–12 days old), as well as GABAB KO
mice and their wild-type littermates (kindly provided by B. Bettler,
Basel, Switzerland) [43] were deeply anaesthetized with isoflurane,
and the brain quickly removed. Slices of VTA or VB thalamus were
prepared as described previously [44,45]. Briefly, the brain was
gluedwith cyanoacrylate adhesive to ametal block and submerged
in the bath of a Leica or Microm MV tissue slicer. The bathing so-
lution was of composition (in mM): NaCl 120, NaHCO3 16, KCl
1, KH2PO4 1.25, MgSO4 5, CaCl2 1, 10 glucose, andwasmaintained
at 58C. Slices (350 mm) were cut in the horizontal plane, and then
stored in a 95% O2, 5% CO2-bubbled solution of identical compo-
sition at room temperature. Following a 1 h recovery period,
experiments were performed in a solution of composition (in
mM): NaCl 120, NaHCO3 16 or 25, KCl 2, KH2PO4 1.25, MgSO4
1, CaCl2 2, 10 glucose, at room temperature (20–248C), unless other-
wise stated. Sliceswere loadedwith Fluo-4AM(Invitrogen, Paisley,
UK) by incubating for 40–60 min at 288Cwith 5 mMof the indicator
dye and 0.01% pluronic acid. TTX (1 mm) was present in theperfusate of all experiments. Agonists (GHB and baclofen) were
bath-applied for 2 min with or without GABABR antagonists
(unless stated otherwise). Chemicals were purchased from Sigma
(St Louis, MO), except CGP65426, MTEP, CNQX, CPCCOEt and
baclofen (Tocris, Bristol,UK),D-APVandTTX (Abcam,Cambridge,
UK), and GHB (that was kindly donated by Unavera ChemLab
GmbH, Mittenwald, Germany).
(b) Fluorescence imaging
The slices were placed in a recording chamber, whereas the
patch-electrode headstage micromanipulators were mounted on
a movable platform (MP MTP-01, Scientifica, UK). Fluorescence
was measured using a Noran Odyssey confocal (Thermo Noran,
USA) fitted to a Nikon E600FN upright microscope. Averages of
eight whole field images (206 mm  158 mm) were routinely
acquired every 5 s with a 40 objective lens (NA ¼ 0.8). Acqui-
sition and image analyses were performed using Noran
Intervision and METAMORPH software. Fluorescence values over
time for specific regions of interest were exported into SIGMAPLOT
(Jandel, USA) for further analysis. The number of responding
astrocytes (reported in the text and figures) is expressed as an
absolute number of responding astrocytes per imaged slice area.
Because the imaged area (see above) was the same in all experi-
ments, and astrocytes are evenly distributed throughout the
brain parenchyma [46], using the absolute number of responding
astrocytes provides a valid and efficient way of determining
agonist and antagonist effects as reported previously [47,48].
Two photon laser scanning microscopy was performed using
a Prairie Ultima (Prairie Technologies, Madison, WI) microscope
and a Ti : sapphire pulsed laser (Chameleon Ultra II, Coherent,
UK) tuned to l ¼ 810 nm. Image acquisition was controlled
using PRAIRIEVIEW software, and laser intensity was modified
using a Pockels cell electroacoustic modulator (ConOptics,
USA). Slices were imaged using a 40/0.8 NA objective lens,
and fluorescence signals from Fluo-4 indicator were collected in
the epicollection mode using multi-alkali photomultiplier tubes
(Hamamatsu Photonics, Hamamatsu, Japan).
(c) Electrophysiology
Patch-clamp recordings from VTA neurons were made using pip-
ettes (2–4 MV) containing an internal solution of composition
(in mM): KMeSO4 120, HEPES 10, EGTA 0.1, Na2ATP 4, GTP
0.5, osmolarity adjusted to 295 mOsm l21 with KCl. Currents
were recorded at 260 mV using a multi-clamp 700B amplifier,
digitized with a Digidata 1440A, and acquired and analysed
using pClamp (Molecular Devices). Neurons with more than
20% change in access resistance were excluded. Slow inward cur-
rents (SICs) were analysed using the event detection protocols in
the Clampfit routine of pClamp. Events were accepted as SICs if
their amplitude was more than 20 pA and their time to peak was
more than 20 ms [47,49]. Data were exported to SIGMAPLOT
(Jandel) for additional analysis and plotting.
(d) Statistics
All quantitative data are expressed in the text as mean+ s.e.m.
Statistical test used was unpaired Student’s t-test. Dose–response
curve fitting was conducted using the fitting procedures of
SIGMAPLOT (Jandel) and PRIZM (GraphPad). In the figures, asterisk
indicates significance of *p, 0.05, **p, 0.005 and ***p, 0.0005.3. Results
In the continuous presence of TTX (1 mM), relatively brief
(2 min) application of GHB to rat VTA slices bulk-loaded
with the Ca2þ indicator Fluo-4 elicited robust and synchronous
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Figure 1. GHB and baclofen elicit [Ca2þ]i transients in VTA and thalamic astrocytes. (a) Fluorescence images of Fluo-4-loaded rat VTA slices before (control) and
during a brief bath application of 10 mM GHB (top) or 10 mM baclofen (bottom) show robust and synchronous [Ca2þ]i transients in response to both drugs. The
transients evoked in astrocytes in the two experiments are shown in fluorescence plots on the right. (b) Dose– response curves of the number of astrocytes respond-
ing to GHB and baclofen (number of slices is indicated below each data point). (c) Fluorescence plots from different preparations of mouse and rat VTA and VB
thalamus show that GABABR activation resulting in [Ca
2þ]i elevations is a general mechanism, i.e. it can be observed in different species and brain regions.
Glutamate (100 mM) applications are also shown for comparison. (Online version in colour.)
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and the electronic supplementary material, movie S1), with
increasing numbers of cells responding to increasing agonist
concentration. The magnitude of GHB-induced elevations
was not different in magnitude to those evoked by the select-
ive GABABR agonist baclofen (figure 1a, bottom row). These
[Ca2þ]i elevations were present in the soma and in the fine
astrocytic processes (electronic supplementary material,
movie S1), and sometimes seen in processes without an appar-
ent clear somatic response. Moreover, the GHB- and baclofen-
elicited [Ca2þ]i transients could be observed in the mouse VTA
(figure 1c) as well as in the rat nucleus accumbens (not shown)
and in themouse and rat VB thalamus (figure 1c). The astrocyt-
ic effect of GHB and baclofen was concentration dependent
with an ED50 of 1.6 mM and 1.3 mM, respectively (figure 1b),
with 10 mM GHB and 10 mM baclofen evoking [Ca2þ]i transi-
ents in 6.82+0.39 astrocytes (n ¼ 11 slices) and 7.14+1.14
astrocytes (n ¼ 14 slices), respectively.
To confirm that GABABRs were indeed mediating the
astrocytic GHB and baclofen responses described above,experiments were conducted using pharmacological and
transgenic interventions. Both GHB and baclofen effects
were virtually abolished by two structurally different
GABABR antagonists, CGP5426 and SCH50911 (baclofen:
p, 1  1025, p, 1  1023, respectively; GHB: p, 1  1027,
p, 1  1025, respectively; figure 2a). Interestingly, GHB
responses were also markedly inhibited by the putative GHB
receptor antagonists NCS382 (GHB: 7.71+0.89 astrocytes,
n ¼ 19 slices; GHB þ NCS382: 1.5+0.46, n ¼ 8, p, 1  1024;
figure 2a), which, however, had no effect on the number
of astrocytes responding to baclofen application (baclofen:
8.5+1.28, n ¼ 8 slices; baclofen þ NCS382: 10+0.57, n ¼ 3
slices). Finally, astrocytes in VTA slices from wild-type litter-
mate mice (WT, GABABR
þ/þ) readily responded with [Ca2þ]i
elevations to GHB and baclofen applications, whereas both ag-
onists failed to elicit astrocytic transients in slices fromGABABR
knockout (GABABR KO,
2/2) mice (figure 2b,c). However,
astrocytes in GABABR KO and WT littermate mice responded
similarly to glutamate (figure 2b,c), thus excluding the pos-
sibility that the mechanism underlying [Ca2þ]i transients in
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Figure 2. GHB and baclofen elicit astrocytic [Ca2þ]i elevations acting via GABABRs. (a) Summary bar graphs showing the number of astrocytes responding to a brief
bath-application of 10 mM GHB and 10 mM baclofen alone or together with one of different GABABR antagonists (as indicated). Astrocyte responses to both drugs
are abolished by the two GABABR antagonists, CGP65426 and Sch50911, whereas the GHB effect, but not that of baclofen, is also inhibited by the putative GHB
receptor antagonist NCS382. Example fluorescence traces are shown on the right. (b) Fluorescence traces from experiments in mouse VTA slices (left column) show
that astrocytes from WT littermates respond to baclofen, whereas in GABABR KO mice baclofen responses are absent though astrocytes still respond to a 100 mM
glutamate application. Similar results are seen in the VB thalamus (right column), indicating common mechanisms for astrocyte [Ca2þ]i elevations in different brain
areas. (c) Summary bar graphs of similar experiments as in (b) showing number of responding astrocytes conducted in VTA for WT (left) and GABABR KO (right)
astrocytes with GHB and baclofen. (Online version in colour.)
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Identical results were obtained in the VB thalamus of
GABABR KO and WT littermate mice (figure 2b,c).
Although all our experiments were conducted in the pres-
ence of TTX to block neuronal activity, the possibility might
exist that the observed effect could be owing to activation of
neuronal GABABRs that resulted in glutamate release and an
indirect effect mediated by the activation of metabotropic
glutamate receptors (mGluRs), which comprise a majorsignalling pathway in astrocytes [50]. As shown in figure 3,
however, the response of VTA astrocytes to both GHB and
baclofen was not affected by APV, NBQX or by the combined
application of mGluR5 and mGluR1 antagonists (MTEP and
CPCCOEt, respectively).
To investigate the sources of signalling elicited by GHB
activation, we manipulated extracellular and intracellular
[Ca2þ]. To deplete intracellular stores, we used the SERCA
pump inhibitor cyclopiazonic acid (CPA; 10 mM), whereas
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Figure 3. GHB- and baclofen-elicited astrocytic [Ca2þ]i transients are unaffected by block of glutamate receptors. Fluorescence traces show responses of astrocytes in
a VTA slice to 10 mM GHB in control conditions and in the presence of APV. The summary bar graph on the right quantifies the lack of effect of NMDA, non-NMDA
and mGluR antagonists (APV, NBQX and MTEPþ CPCCOEt, respectively) on the number of astrocytes responding to application of 10 mM GHB or 10 mM baclofen.
(Online version in colour.)
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and baclofen in slices bathed with a nominal extracellular
Ca2þ-free solution. Responses to baclofen were significantly
reduced by both interventions (ctrl: 5.75+ 0.70 astrocytes,
n ¼ 12 slices; CPA: 0.3+ 0.15, n ¼ 12, p, 1  1028; 0 mM
Ca2þ: 0.22+ 0.11, n ¼ 12, p, 1  1028) as were those to
GHB (ctrl: 5.6+0.56, n ¼ 12; CPA: 0.28+ 0.88, n ¼ 16, p,
1  1025; 0 mM Ca2þ: 0.46+ 0.13, n ¼ 12, p, 1  1025),
showing that the effects of both agonists are dependent on
Ca2þ release from intracellular stores and an extracellular
Ca2þ supply, as previously described for similar [Ca2þ]i
transients observed spontaneously and evoked by other
neurotransmitter agonists [51,52].
We have previously shown that the sustained stimulation
of G-protein coupled mGluRs either by synaptic glutamate
release or by agonist exposure results in an increase in the
frequency of spontaneous astrocyte [Ca2þ]i oscillations
which is associated with a [Ca2þ]i-dependent increase in the
frequency of astrocytic glutamate release events, i.e. neuronal
SICs [49,53]. To investigate whether a similar phenomenon
resulted from sustained GABABR activation, we applied
GHB and baclofen for increasing durations to VTA slices.
Although our experiments show that a 2 min baclofen appli-
cation elicited astrocyte [Ca2þ]i elevations (figures 1–3), a
3 min pre-exposure did not lead to an increase in the
number of spontaneous astrocytic [Ca2þ]i transients, whereas
following a 15 min pre-exposure to baclofen spontaneous
astrocyte activity was reduced compared with control slices
(ctrl: 7.16+ 0.54 astrocytes, n ¼ 8 slices; baclofen 15 min:
1.78+ 0.32, n ¼ 12, p, 1  1025; figure 4a). Exposure to
GHB also resulted in a reduction that approached statistical
significance (ctrl: 6.3+1.12, n ¼ 12, GHB 15 min: 4.0+0.5,
n ¼ 12, p ¼ 0.069; figure 4a). To test whether these changes
in spontaneous [Ca2þ]i signalling were translated to spon-
taneous astrocyte–neuron glutamatergic signalling recorded
as SICs, we therefore treated VTA slices with baclofen or
GHB for extended periods of 1–3 h and compared these
results with those of untreated slices. Patch-clamp recordings
made from VTA neurons in the presence of TTX showed
the presence of spontaneous SICs in the VTA, confirming the
existence of spontaneous astrocyte–neuron signalling in this
brain area (figure 4b). Short (3 min) pre-incubation of the
slice with baclofen application, however, did not induce
astrocytic glutamate release as measured by SIC recording
(ctrl: 0.056+ 0.016 SICs per min, n ¼ 11 slices; baclofen:
0.086+0.027, n ¼ 11, p ¼ 0.2). Nevertheless, in agreement
with the observed decrease in astrocytic [Ca2þ]i elevationsobserved during prolonged GABABR activation (1–3 h), SIC
frequency was significantly reduced by sustained pre-
exposure to GHB and baclofen (ctrl: 0.066+ 0.017 SICs per
min, n ¼ 28 slices; baclofen: 0.026+0.009, n ¼ 26, p, 0.05;
GHB: 0.01+0.008, n ¼ 11, p, 0.05; figure 4c, right plot).4. Discussion
The main findings of this study are that GHB consistently eli-
cits robust [Ca2þ]i transients in astrocytes of both the VTA
and the VB thalamus of young rodents, two brain areas
that are involved in the reward properties and the pro-
absence effect of this drug, respectively. This astrocytic
GHB action is mediated by GABABRs and is comparable to
that evoked in astrocytes of the same regions by the selective
GABABR agonist baclofen. Moreover, prolonged GHB
and baclofen exposure causes a reduction in spontaneous
glutamate release from VTA astrocytes.
(a) Astrocytic gamma-hydroxybutyric acid effects
The astrocytic response to GHB (and baclofen) was highly
reliable and consistent from trial to trial in the age range
tested, and thus did not show the variability that has been
reported in a previous study [42]. Determination of whether
there is a difference in age-dependent GABABR signalling
that is also region-dependent will require further studies in
the VTA and VB thalamus.
Both GHB- and baclofen-elicited [Ca2þ]i transients were
(i) abolished by two highly selective but structurally dissimilar
GABABR antagonists, (ii) absent in GABABR KO mice and
(iii) unaffected by the block of ionotropic andmetabotropic glu-
tamate receptors, indicating that in astrocytes, as occurs in
neurons, the action of GHB is mediated by GABABRs. Indeed,
the 1000-fold difference in the ED50 of the two drugs on astrocy-
tic responses is very similar to that reported for their activation
of pre- and post-synaptic neuronal GABABRs, including hyper-
polarization of the membrane potential and inhibition of
synaptic potentials [54]. However, the astrocytic effect of GHB
was also markedly blocked by NCS382, an antagonist of the
putative GHB receptor. This represents the first solid evidence
of a CNS action of GHB beingmediated by its putative receptor
[3], and might provide an explanation for the block of GHB-
elicited absence seizures observed in some studies [34]. Finally,
the lack of action of ionotropic and metabotropic glutamate
receptors on GHB-elicited [Ca2þ]i transients indicates that
these responses are not mediated by activation of astrocytes
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Figure 4. Time-dependent effect of GHB and baclofen on astrocytic [Ca2þ]i signalling and glutamate release. (a) Fluorescence traces show spontaneous astrocytic
[Ca2þ]i transients in control conditions and in a VTA slice pre-exposed to 10 mM baclofen for 15 min. Bar graphs on the right summarize data from similar experi-
ments where slices were pre-exposed to either 10 mM baclofen or 10 mM GHB for 3 and 15 min. (b) Patch-clamp recording from a VTA neuron on an expanded
timebase illustrating spontaneous SICs in control conditions (top trace), and lower trace showing effect of long duration 10 mM baclofen application (SICs high-
lighted by filled circle). (c) Summary data showing the frequency of SICs in control conditions, and following long (.1 h) exposure to either 10 mM GHB or 10 mM
baclofen. (Online version in colour.)
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that they results from direct activation of astrocytic GABABRs.
GHB- (and baclofen)-elicited [Ca2þ]i transients were
blocked following perfusion of VTA slices with either a nom-
inal extracellular Ca2þ-free solution or with CPA. Thus, our
results indicate that both GHB and baclofen astrocytic
responses in VTA involve intracellular Ca2þ stores and their
refilling by extracellular Ca2þ. Whether GHB activity requires
Gi/o proteins (which are classically associated with neuronal
GABABR activation) or Gq proteins (which have been strongly
linked to Ca2þ release from intracellular stores) remains to be
elucidated, as is indeed the case for the astrocytic response to
baclofen in VTA or any other brain region.
Finally, in contrast to the activation of astrocytes, brief
application of GHB and baclofen had no effect on spontaneous
[Ca2þ]i transients (see control grey bar in figure 4a), but
decreased their frequency when applied for periods of
15 min or longer. A similar picturewas obtained when looking
at spontaneous SICs, the neuronal counterpart of astrocytic
released glutamate, suggesting that long-term activation of
GABABR lead to a reduction in the glutamate-dependent
astrocyte to neuron signalling.
(b) Potential ( patho)physiological implications of
gamma-hydroxybutyric acid activation of astrocytes
Our finding of an astrocytic activation by GHB opens new av-
enues in the interpretation of the effects of this substance.As faras absence seizures are concerned, our results suggest for the
first time that the ability of GHB to induce these seizures
might involve an astrocytic component togetherwith a neuron-
al component. This, together with the already described loss of
function of GAT1 in thalamic astrocytes of genetic models of
absence seizures [29] and the fact that GABA transporters
affect astrocytic [Ca2þ]i transients [55], clearly stresses the
importance of this glial cell type in the generation of these
non-convulsive seizures. Finally, our data showing a block of
GHB-elicited astrocytic [Ca2þ]i transients by NCS382 provide
a potential explanation for the anti-absence effect of this puta-
tive GHB receptor antagonist, the action of which had so far
been difficult to reconcile with its lack of action on neuronal
response in thalamus [3], one of the key regions responsible
for the generation of these non-convulsive seizures.
Drugs that cause addiction act in the VTA to increase dopa-
mine release in target areas, notably the nucleus accumbens. It
has been suggested that GHB achieves this by inhibiting
GABAergic interneuron activity which results in disinhibition
of dopaminergic neurons in the VTA, and so increased dopa-
mine release [56,57]. Our observations suggest a possible
astrocytic contribution to such amechanism, if a reduced astro-
cytic glutamate release which may ordinarily contribute to
tonic glutamate has a physiological role in driving GABAergic
interneuron activity. Reducing such a drivewould therefore be
expected to increase the output of dopaminergic neurons.
There are reports from many brain areas of a Ca2þ-dependent
gliotransmitter release increase following the activation of
rstb.royalsocietypublishing.org
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 on September 30, 2014rstb.royalsocietypublishing.orgDownloaded from G-protein coupled receptors [58]: these examples are linked to
PLC and IP3 production via Gq, whereas GABABRs are
coupled to adenylyl cyclase via Gi/o [54]. We found that in
astrocytes, GABABR activation elicits [Ca
2þ]i elevations. The
mechanismunderlying this increase is unclear butmay involve
some activation of Gq-coupled pathways, or novel interactions
between GABAB auxiliary subunits and intracellular Ca
2þ
release pathways. Whatever the physiological role of the
GABABR-induced [Ca
2þ]i elevations, it does not seem to
invoke glutamate gliotransmitter release. It does, however,
provide an experimental reporter of astrocyte GABABR acti-
vation, and our observations are consistent with dominant
activation of non-Gq pathways, because we found a reductionin spontaneous gliotransmitter glutamate release (i.e. SICs).
Interestingly, this observation is analogous to the effect of
GABABR activation on inhibiting spontaneous presynaptic
neurotransmitter release [59], and indicates the complexity of
signalling pathways which may influence the ways that
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